OncoMatch/Clinical Trials/NCT06683066
Study on Human Bioequivalence of Triprerelin Acetate for Injection
Is NCT06683066 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Triprorelin for and Diphereline for prostate cancer (crpc).
Treatment: Triprorelin for · Diphereline — To investigate the pharmacokinetics of triprerelin acetate for injection and triprerelin acetate (Dufferin ®) for injection of reference preparation in patients with prostate cancer by single intramusculodynamic injection in fasting state, and to evaluate the bioequivalence of the two formulations in fasting state.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: gonadotropin-releasing hormone analogue
Patients who have previously been treated with a gonadotropin-releasing hormone analogue (GnRHa) and who have been evaluated by the investigators as suitable for treatment with GNRHA
Must have received: triprerelin acetate (triprerelin acetate)
Patients receiving stable treatment with triprerelin acetate for injection
Cannot have received: surgical castration
Patients who have previously undergone surgical castration
Cannot have received: adrenalectomy
Patients who have previously undergone adrenalectomy
Cannot have received: pituitary resection
Patients who have previously undergone ... pituitary resection
Lab requirements
Blood counts
adequate hematopoietic function
Kidney function
adequate kidney function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify